Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 11, 2014

Hilleman signs MoU with Bangladesh firms to develop oral cholera vaccine

Hilleman Laboratories, a joint venture of Merck and Wellcome Trust, has signed a memorandum of understanding (MoU) with Bangladesh-based icddr,b and Incepta Vaccine to develop an oral cholera vaccine.

Hillmen

Hilleman Laboratories, a joint venture of Merck and Wellcome Trust, has signed a memorandum of understanding (MoU) with Bangladesh-based icddr,b and Incepta Vaccine to develop an oral cholera vaccine.

The collaboration was established to fast track the clinical trials and product licensing, as well as commercialisation of the product.

Hilleman Laboratories CEO Davinder Gill said: "We are thrilled to partner with icddr,b and Incepta, two highly specialised entities headquartered in Dhaka.

"This collaboration will allow the three organisations to work together and bring forward a cheap effective cholera vaccine to meet the needs of the developing world."

As part of the deal, Hilleman will provide its expertise, including the process, formulation and pre-clinical development, for the clinical trials of the vaccine candidate.

"With an estimated 100,000-120,000 deaths and a morbidity of 3.8-4.4 million annual cases, cholera is endemic in more than 50 countries."

Expertise related to clinical development and studies of the vaccine candidate will be offered by icddr,b.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Incepta will extend its support to the programme for process development, scale-up and cGMP manufacturing for pre-clinical and clinical trials.

Executive director of icddr,b Dr John Clemens said: "Cholera is a major public health problem in several developing countries and we are excited for the opportunity to translate research into prevention.

"An important challenge is to understand the effectiveness of vaccines in resource poor, high-risk settings. For a variety of reasons, responses to oral vaccines in the developing world are often lower than those seen in industrialised countries."

With an estimated 100,000-120,000 deaths and a morbidity of 3.8-4.4 million annual cases, cholera is endemic in more than 50 countries.


Image: Hilleman Laboratories, New Delhi, India. Photo: courtesy of Hillema Laboratories.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU